Advertisement
Phase 2b trial of aldosterone synthase inhibitor also finds no benefit from dose escalation
General principles for use of the long-awaited new therapy approach
Getting patients to their goal blood pressure
Companion analyses find 7% prevalence, linkage to worse outcomes
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Advertisement
Advertisement